Skip to content

The effect of Autologous Platelet-Rich Plasma (PRP) on ovarian function

The effect of Autologous Platelet-Rich Plasma (PRP) on ovarian function in patients with premature ovarian failure and poor ovarian reserve

Status
Active, not recruiting
Phases
Phase 2
Study type
Interventional
Source
IRCT
Registry ID
IRCT20180818040828N2
Enrollment
30
Registered
2018-11-22
Start date
2018-09-01
Completion date
Unknown
Last updated
2021-04-26

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Condition 1: Premature ovarian failure. Condition 2: Poor ovarian responders. Female infertility associated with anovulation Female infertility associated with anovulation

Interventions

Intervention 1: First intervention group(premature ovarian failure): At first test serum AMH, estradiol (E2), FSH and LH a few days before intervention. In intervention day PRP process with Rooyagen k

Sponsors

Yazd University of Medical Sciences
Lead Sponsor

Eligibility

Sex/Gender
Female
Age
20 Years to 42 Years

Inclusion criteria

Inclusion criteria: Patient with premature ovarian failure patient with poor ovarian reserve (AFC<5-7 and AMH<0.5-1.1 ng/ml)

Exclusion criteria

Exclusion criteria: IgA deficiency Ovarian failure secondary to sex chromosome abnormality Pelvic adhesion scondary to abdominal surgery Chronic pelvic pain

Design outcomes

Primary

MeasureTime frame
FSH level. Timepoint: Some days before injection and 1, 2 months after injection. Method of measurement: Check in labratory.;AMH level. Timepoint: Some days before injection and 1, 2 months after injection. Method of measurement: Check in labratory.;Estradiol level. Timepoint: Some days before injection and 1, 2 months after injection. Method of measurement: Check in labratory.;LH level. Timepoint: Some days before injection and 1, 2 months after injection. Method of measurement: Check in labratory.

Secondary

MeasureTime frame
Chemical pregnancy. Timepoint: 1 year after the first PRP injection. Method of measurement: Laboratory measurement of Beta hCG.;Clinical pregnancy. Timepoint: 5 weeks after positive Beta hCG. Method of measurement: Observation of fetal heart rate in sonography.;Live birth. Timepoint: 36 weeks after positive Beta hCG. Method of measurement: Delivery of live-born baby.

Countries

Iran (Islamic Republic of)

Contacts

Public ContactDr.Lida Saeed

Yazd University of Medical Sciences

lsaeed6@yahoo.com+98 35 3824 7085

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 4, 2026